Studies on Epigenetically Active Latent Chromatin Maintenance
Project Number5R01AI167663-04
Former Number1R01AI167663-01
Contact PI/Project LeaderIZUMIYA, YOSHIHIRO
Awardee OrganizationUNIVERSITY OF CALIFORNIA AT DAVIS
Description
Abstract Text
Deregulation of genome interactions through mutations at regulatory elements or mutation of responsible
cellular nuclear enzymes result in multiple disorders. Although the significance of proper genomic-genomic
interactions has been seen from disease phenotypes, the underlying molecular mechanisms of genomic looping
regulation and the direct outcome of transcription are still not well connected. This partly stems from the highly
complex nature of cellular promoter regulation, since it is controlled by multiple transcriptional factors and enhancer
elements with significant noise within cell populations.
Transcriptomics, genomics, and proteomics studies with recombinant Kaposi's sarcoma-associated
herpesvirus (KSHV) episomes identified that the host cellular ChAHP (CHD4, ADNP, HP1) protein complex forms a
stable protein complex with KSHV latency associated nuclear antigen (LANA) and plays essential roles in maintaining
the inducibility of latent viral chromatin. The ChAHP complex is known to restrict cellular enhancer accessibility and
regulates cell lineage, although how the protein complex regulates enhancer-promoter interaction remains unknown.
Here, we hypothesize that the KSHV latency-lytic switch is a product of enhancer-promoter interactions regulated by
the LANA-ChAHP complex. In this application, we will study how the KSHV episome is maintained as an inducible
episome and if we can target the protein complex for therapeutic intervention. The molecular action of the
LANA/ChAHP protein complex will be studied from three different perspectives; (i) biochemical, (ii) genetic, and (iii)
protein complex structure. By taking advantage of defined enhancer-promoter pairs and convenient inducible mini
viral chromatin, we will study enhancer-promoter regulations by dissecting ChAHP protein complex function. The
proposed studies should not only benefit the understanding of the KSHV latency-lytic switch, but also provide insight
into cellular inducible enhancer regulatory mechanisms.
Public Health Relevance Statement
Project Narrative
Transcriptional memory is a biological phenomenon first described in yeast genetics studies and now
widely seen in other organisms. Using the well-organized herpesvirus mini-chromosome as a tool to
replicate the phenotypes and study molecular mechanisms is a very convenient, efficient, and highly
cost-effective approach to understand underlining mechanisms of enhancer-promoter regulations.
Understand how transcription memory (latent KSHV chromatin) is maintained will help us to understand
regulation of herpesvirus latency.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
047120084
UEI
TX2DAGQPENZ5
Project Start Date
10-February-2022
Project End Date
31-January-2027
Budget Start Date
01-February-2025
Budget End Date
31-January-2026
Project Funding Information for 2025
Total Funding
$517,813
Direct Costs
$321,623
Indirect Costs
$196,190
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Allergy and Infectious Diseases
$517,813
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI167663-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI167663-04
Patents
No Patents information available for 5R01AI167663-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI167663-04
Clinical Studies
No Clinical Studies information available for 5R01AI167663-04
News and More
Related News Releases
No news release information available for 5R01AI167663-04
History
No Historical information available for 5R01AI167663-04
Similar Projects
No Similar Projects information available for 5R01AI167663-04